1-azabicyclo-[3.2.2]nonan-3,4-dione-3-oxime | 171087-18-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环庚烷
• 英文名称: 1-azabicyclo-[3.2.2]nonan-3,4-dione-3-oxime
• 英文别名: 1-Azabicyclo[3.2.2]nonan-3,4-dione-3-oxime；3-hydroxyimino-1-azabicyclo[3.2.2]nonan-4-one
• CAS: 171087-18-6
• 化学式: C₈H₁₂N₂O₂
• 分子量: 168.195
• InChiKey: IOHYJBRAIGFSJQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  52.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-azabicyclo-[3.2.2]nonan-3,4-dione-3-oxime 在 palladium dihydroxide sodium hydroxide 、 草酰氯 、 乙醇 、 氢气 、 sodium 、 N,N-二甲基甲酰胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 生成 (+/-)-trans-1-aza-3-(4-hydroxybenzamido)-4-({4-[2-hydroxy-6-(hydroxycarbonyl)benzoyl]-3,5-dihydroxybenzoyl}oxy)bicyclo[3.2.2]nonane
  参考文献：
  名称：

  Synthesis and Protein Kinase C Inhibitory Activities of Balanol Analogs with Replacement of the Perhydroazepine Moiety

  摘要：

  Balanol is a potent protein kinase C (PKC) inhibitor that is structurally composed of a benzophenone diacid, a 4-hydroxybenzamide, and a perhydroazepine ring. A number of balanol analogs in which the perhydroazepine moiety is replaced have been synthesized and their biological activities evaluated against both PKC and cAMP-dependent kinase (PKA). The results suggested that the activity and the isozyme/kinase selectivity of these compounds are largely related to the conformation about this nonaromatic structural element of the molecules.

  DOI：

  10.1021/jm960497g
• 作为产物：
  描述：

  3-奎宁环酮 在 丁腈 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 1-azabicyclo-[3.2.2]nonan-3,4-dione-3-oxime
  参考文献：
  名称：

  Synthesis and Protein Kinase C Inhibitory Activities of Balanol Analogs with Replacement of the Perhydroazepine Moiety

  摘要：

  Balanol is a potent protein kinase C (PKC) inhibitor that is structurally composed of a benzophenone diacid, a 4-hydroxybenzamide, and a perhydroazepine ring. A number of balanol analogs in which the perhydroazepine moiety is replaced have been synthesized and their biological activities evaluated against both PKC and cAMP-dependent kinase (PKA). The results suggested that the activity and the isozyme/kinase selectivity of these compounds are largely related to the conformation about this nonaromatic structural element of the molecules.

  DOI：

  10.1021/jm960497g

文献信息

• Substituted fused and bridged bicyclic compounds as therapeutic agents
  申请人：Eli Lilly and Company

  公开号：US05583221A1

  公开（公告）日：1996-12-10

  Compounds having the formula ##STR1## methods for using such compounds to inhibit protein kinase C in animals, including man are useful as inhibitors of protein kinase C. Also disclosed are pharmaceutical compositions including such compounds and compounds having the formula.

  化合物的分子式为##STR1##的化合物，使用这种化合物的方法可以抑制动物中的蛋白激酶C，包括人类，这些化合物是蛋白激酶C的抑制剂。还披露了包括这些化合物和分子式的药物组合物。